Allergan $AGN posted Q3 EPS of $3.32, missing the guidance by $0.26. Revenue was $3.62 billion, a 4.3% growth, Y-o-Y, missing the forecast by $70 million. For the quarter, GAAP Q3 operating loss from continuing operations was $266 million. Non-GAAP adjusted operating income from continuing operations was $1.78 billion.